Ipsen (CHIX:IPNP) Accumulated Depreciation: €-591 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:IPNP Ipsen SA CHIX:IPNP
94 GF Score
Price €158.95
GF Value €138.98
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Ipsen Accumulated Depreciation?

Ipsen CHIX:IPNP 94 Accumulated Depreciation is €-591 Mil as of Jun. 2026. GuruFocus rates CHIX:IPNP with a GF Score™ of 94/100 and a GF Value™ of €138.98 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Ipsen's quarterly accumulated depreciation declined from Jun. 2025 (€-616 Mil) to Dec. 2025 (€-575 Mil) but then increased from Dec. 2025 (€-575 Mil) to Jun. 2026 (€-591 Mil).

Ipsen's annual accumulated depreciation increased from Dec. 2023 (€-556 Mil) to Dec. 2024 (€-617 Mil) but then stayed the same from Dec. 2024 (€-617 Mil) to Dec. 2025 (€-575 Mil).

Ipsen Accumulated Depreciation Related Terms

Ipsen Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Ipsen's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen Accumulated Depreciation Chart

Ipsen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -642.50 0.00 -555.60 -616.90 -574.80

Ipsen Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -586.10 -616.90 -615.90 -574.80 -590.60
CHIX:IPNP
94GF Score
Ipsen SA CHIX:IPNP
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipsen Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of €-591 Mil mean?
Ipsen (CHIX:IPNP) has a Accumulated Depreciation of €-591 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Ipsen and its competitors.
Is Ipsen's Accumulated Depreciation too high?
Ipsen's current Accumulated Depreciation is €-591 Mil. Overall, Ipsen has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipsen's Accumulated Depreciation compare to ZTS and UTHR?
Ipsen's Accumulated Depreciation of €-591 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Drug Manufacturers company?
A good Accumulated Depreciation depends on the Drug Manufacturers industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Ipsen and its competitors. Ipsen's current Accumulated Depreciation is €-591 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Based on GuruFocus' analysis, Ipsen (CHIX:IPNP) is currently considered Modestly Overvalued. The stock's GF Value™ is €138.98, compared to a current price of €158.95 — trading 14.4% above its estimated fair value. The current Accumulated Depreciation is €-591 Mil. Ipsen's overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Ipsen (CHIX:IPNP), the current Accumulated Depreciation is €-591 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipsen (CHIX:IPNP) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €158.95 is trading 14.4% above its estimated GF Value™ of €138.98. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for CHIX:IPNP:

  • Accumulated Depreciation: €-591 Mil
  • GF Value™: €138.98 vs. price of €158.95 (14.4% above fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the CHIX:IPNP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
94GF Score

Get the complete analysis for CHIX:IPNP

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€158.95
Price
€138.98
GF Value